文献速递主动脉疾病

血管腔内动脉瘤修复术中应用形状记忆聚合物装置主动治疗主动脉瘤囊的一年随访

One-year follow-up after active aortic aneurysm sac treatment with shape memory polymer devices during endovascular aneurysm repair.
PubMed 文献 · J Vasc Surg · 2024-01-05

两项前瞻性、多中心、单臂研究在新西兰和荷兰开展,纳入34例接受择期肾下腹主动脉瘤EVAR的成人患者,术中即刻用聚氨酯形状记忆聚合物装置填充目标管腔。技术成功率为100%,1年时标准化囊腔体积较基线平均下降28.8%(95%CI -35.3至-22.3%,P<.001),囊腔直径平均缩小5.9 mm(95%CI -7.5至-4.4 mm,P<.001),未发生装置或研究操作相关的主要不良事件。

要点

  • 34例患者中33例可评估1年,技术成功率为100%。
  • 1年标准化囊腔体积较基线平均下降28.8%(95%CI -35.3至-22.3%,P<.001)。
  • 1年囊腔直径较基线平均缩小5.9 mm(95%CI -7.5至-4.4 mm,P<.001)。

核心结论

  • 在这项前瞻性研究中,EVAR术中应用SMP装置治疗AAA囊腔在1年时使囊腔体积和直径显著回缩,安全性可接受。

研究设计与样本

  • 在新西兰和荷兰开展两项完全相同的前瞻性、多中心、单臂研究,纳入拟择期EVAR的肾下AAA成人患者(男性直径≥55 mm,女性≥50 mm)。
  • 34例患者接受SMP装置治疗并按方案随访,其中33例在1年时可评估。
  • 主要疗效终点为技术成功,即术毕完全展开的SMP填充实际目标管腔体积。

主要发现

  • 术前动脉瘤体积为181.4 mL(95%CI 150.7-212.1 mL),术前动脉瘤直径为60.8 mm(95%CI 57.8-63.9 mm)。
  • 目标管腔体积为56.3 mL(95%CI 46.9-65.8 mL),技术成功率为100%,SMP完全展开体积与估计目标管腔体积之比为1.4±0.3。
  • 基线标准化囊腔体积和直径分别为140.7 mL(95%CI 126.6-154.9 mL)和61.0 mm(95%CI 59.7-62.3 mm)。
  • 1年时标准化体积的校正平均百分比变化为-28.8%(95%CI -35.3至-22.3%,P<.001),囊腔直径的校正平均变化为-5.9 mm(95%CI -7.5至-4.4 mm,P<.001)。
  • 1年时81.8%的患者(95%CI 64.5%-93.0%)实现标准化体积下降≥10%,57.6%的患者(95%CI 39.2%-74.5%)实现直径下降≥5 mm;至术后1年未发生装置或研究操作相关的主要不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the safety and efficacy of treating abdominal aortic aneurysm (AAA) sacs with polyurethane shape memory polymer (SMP) devices during endovascular aneurysm repair (EVAR), using a technique to fully treat the target lumen after endograft placement (aortic flow volume minus the endograft volume). SMP devices self-expand in the sac to form a porous scaffold that supports thrombosis throughout its structure. METHODS: Two identical prospective, multicenter, single-arm studies were conducted in New Zealand and the Netherlands. The study population was adult candidates for elective EVAR of an infrarenal AAA (diameter of ≥55 mm in men and ≥50 mm in women). Key exclusion criteria were an inability to adequately seal a common iliac artery aneurysm, patent sac feeding vessels of >4 mm, and a target lumen volume of <20 mL or >135 mL. Target lumen volumes were estimated by subtracting endograft volumes from preprocedural imaging-based flow lumen volumes. SMP devices were delivered immediately after endograft deployment via a 6F sheath jailed in a bowed position in the sac. The primary efficacy end point was technical success, defined as filling the actual target lumen volume with fully expanded SMP at the completion of the procedure. Secondary efficacy outcome measures during follow-up were the change in sac volume and diameter, rate of type II endoleak and type I or III endoleaks, and the rate of open repair and related reinterventions, with data collection at 30 days, 6 months, and 1 year (to date). Baseline sac volumes and diameters for change in sac size analyses were determined from 30-day imaging studies. Baseline and follow-up volumes were normalized by subtraction of the endograft volume. RESULTS: Of 34 patients treated with SMP devices and followed per protocol, 33 patients were evaluable at 1 year. Preprocedural aneurysm volume was 181.4 mL (95% confidence interval [CI], 150.7-212.1 mL) and preprocedural aneurysm diameter was 60.8 mm (95% CI, 57.8-63.9 mm). The target lumen volume was 56.3 mL (95% CI, 46.9-65.8 mL). Technical success was 100% and the ratio of SMP fully expanded volume to estimated target lumen volume was 1.4 ± 0.3. Baseline normalized sac volume and diameter were 140.7 mL (95% CI, 126.6-154.9 mL) and 61.0 mm (95% CI, 59.7-62.3 mm). The adjusted mean percentage change in normalized volume at 1 year was -28.8% (95% CI, -35.3 to -22.3%; P < .001). The adjusted mean change in sac diameter at 1 year was -5.9 mm (95% CI, -7.5 to -4.4 mm; P < .001). At 1 year, 81.8% of patients (95% CI, 64.5%-93.0%) achieved a ≥10% decrease in normalized volume and 57.6% of patients (95% CI, 39.2%-74.5%) achieved a ≥5 mm decrease in diameter. No device- or study procedure-related major adverse events occurred through 1 year after the procedure. CONCLUSIONS: Treatment of AAA sacs with SMP devices during EVAR resulted in significant sac volume and diameter regression at 1 year with an acceptable safety profile in this prospective study.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Holden A, Hill AA, Khashram M, et al. One-year follow-up after active aortic aneurysm sac treatment with shape memory polymer devices during endovascular aneurysm repair. J Vasc Surg. 2024. PMID: 38185214. doi:10.1016/j.jvs.2023.12.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。